AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
Yatra Online stock target cut to $3 at H.C. Wainwright, retains Buy rating
H.C. Wainwright analyst Scott Buck revised the price target on Yatra Online (NASDAQ:YTRA) to $3.00 from the previous $4.00, while maintaining a Buy rating on the company's stock. The adjustment ...
Arvinas price target lowered to $81 from $87 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Arvinas (ARVN) to $81 from $87 and keeps a Buy rating on the shares. Given the company’s ...
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...
FY2025 EPS Estimates for Eyenovia Boosted by HC Wainwright
Equities researchers at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of Eyenovia in a note issued to investors on Thursday, February 6th. HC Wainwright analyst M.
Hosted on MSN2d
HC Wainwright & Co. Downgrades Pliant Therapeutics (PLRX)
Fintel reports that on February 10, 2025, HC Wainwright & Co. downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX ...